GlassScriptPhysician profile
Javier G Taboada
NPI 1780731802
$710.76
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $28.57 · 2021: $194 · 2022: $254.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $213.71 | 2019-2022 | |
| Eisai INC. | $137.98 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $72.31 | 2021-2022 | |
| Boston Scientific Corporation | $51.30 | 2022 | |
| Biogen, INC. | $46.70 | 2019-2021 | |
| Lundbeck LLC | $43.34 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.69 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $27.00 | 2019 | |
| Sk Life Science, INC. | $21.69 | 2021 | |
| Mallinckrodt Enterprises LLC | $15.62 | 2019 | |
| Argenx US, INC. | $14.56 | 2022 | |
| Avanir Pharmaceuticals, INC. | $13.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.31 | 2019 | |
| Neurocrine Biosciences, INC. | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Taboada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.